Anti-Cancer Clinical Compound Library
Ref. TM-L2120
1mg | A consultar | |
30µl*10 (DMSO) | A consultar | |
50µl*10 (DMSO) | A consultar | |
100µl*10 (DMSO) | A consultar | |
250µl*10 (DMSO) | A consultar |
Información del producto
A unique collection of 2614 anti-cancer compounds for high throughput screening (HTS) and high content screening (HCS);
- Bioactivity confirmed by pre-clinical research and all of them are currently in clinical trial phases, representing the cutting-edge treatments for cancers;
- Effective tool for cancer research and drug repurposing screening;
- Covers various major targets including PI3K, HDAC, mTOR, CDK, Aurora Kinase, JAK, etc., in lung cancer, breast cancer, leukemia, lymphoma, etc.
- Detailed compound information with structure, target, activity, IC50 value, and biological activity description;
- Structurally diverse, medicinally active, and cell permeable;
- NMR and HPLC validated to ensure high purity and quality;
Propiedades químicas
Consulta técnica sobre: TM-L2120 Anti-Cancer Clinical Compound Library
Si desea solicitar un presupuesto o realizar un pedido, por favor añada los productos deseados a su carrito y solicite un presupuesto o pedido desde el carrito. Es más rápido, más barato, y podrá beneficiarse de los descuentos y las ventajas disponibles.